Similares a William Feldman, MD: Azithromycin Over Roflumilast in Real World COPD Data

20 vecinos (text_768) · 182 views · HCPLive · Estados Unidos


★	William Feldman, MD: Azithromycin Over Roflumilast in Real World COPD Data	HCPLive @hcplivenews	182	Estados Unidos
1	Mepolizumab Add-On Reduces COPD Exacerbations in Triple-Therapy Patients \| ATS 2026	HCPLive @hcplivenews	1.2K	Estados Unidos	85
11	Efdoralprin Alfa Normalizes Alpha-1 Antitrypsin Levels I #ats2026	HCPLive @hcplivenews	548	Estados Unidos	83
14	What Heart Rate and 6-Minute Walk Test Reveal About #COPD Exacerbation Risk	HCPLive @hcplivenews	548	Estados Unidos	82
15	Avances terapéuticos en Hipertensión Pulmonar y su impacto en pacientes con comorbilidades	FAC @fac_cardio	209	Argentina	82
6	Mixed AERIFY Data May Delay Itepekimab Approval Pathway in COPD, With Klaus F. Rabe, MD, PhD	HCPLive @hcplivenews	198	Estados Unidos	84
5	Efdoralprin Alfa vs Standard of Care in AATD: Phase 2 ElevAATe Results	HCPLive @hcplivenews	156	Estados Unidos	84
19	REACH Study: Broncho-Vaxom (OM-85) Cuts Recurrent Respiratory Tract Infections	HCPLive @hcplivenews	134	Estados Unidos	82
9	Tezepelumab Reduced Severe Asthma Exacerbations Across Phenotypes \| ATS 2026	HCPLive @hcplivenews	122	Estados Unidos	83
20	Phase 3b ENCORE: ALIS Improves MAC Lung Disease Outcomes \| ATS 2026	HCPLive @hcplivenews	117	Estados Unidos	82
18	COPD Flare-Ups: What Triggers Them and What to Do	University of Maryland Medical System @universityofmarylandmedica3585	116	Estados Unidos	82
2	Mepolizumab Reduced COPD Hospitalizations in Eosinophilic Disease \| ATS 2026 With Gerard Criner, MD	HCPLive @hcplivenews	113	Estados Unidos	84
8	AERIFY: Phase 3 Data Reveal Challenges, Potential of Itepekimab in COPD	HCPLive @hcplivenews	105	Estados Unidos	83
17	Brensocatib, 1 Year Later: Who Benefits Most? \| Mark Metersky, MD	HCPLive @hcplivenews	98	Estados Unidos	82
4	Efdoralprin Alfa vs Standard of Care in AATD: Phase 2 ElevAATe Results	HCPLive @hcplivenews	82	Estados Unidos	84
16	ATS 2026 Asthma Updates: Tezepelumab, Dupilumab, OCS Reduction & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	70	Estados Unidos	82
10	Tezepelumab Cuts Severe Asthma Exacerbations 70% in Real-World Patients \| ATS 2026	HCPLive @hcplivenews	68	Estados Unidos	83
12	ATS 2026 Pulmonology: AD109, Ralinepag, ALIS, Itepekimab & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	55	Estados Unidos	83
7	SGLT2 Inhibitors May Reduce COPD Readmissions I ATS 2026	HCPLive @hcplivenews	48	Estados Unidos	83
13	Helping Patients Breathe Easier \| Lynn Bingaman, CRNP at Geisinger	Geisinger @geisingerhealth	45	Estados Unidos	82
3	Pegtarazimod Cuts Oxygen Need in Hospitalized COPD Patients \| ATS 2026 \| Gerald Criner, MD	HCPLive @hcplivenews	29	Estados Unidos	84